Xeris Biopharma (NASDAQ:XERS) Sets New 12-Month High – Still a Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares hit a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $11.42 and last traded at $10.95, with a volume of 4,340,782 shares changing hands. The stock had previously closed at $10.31.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Leerink Partners upped their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Barclays raised their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 6th. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Finally, Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Xeris Biopharma currently has a consensus rating of “Hold” and a consensus target price of $13.20.

Xeris Biopharma Price Performance

The company has a market cap of $1.97 billion, a price-to-earnings ratio of -98.00 and a beta of 0.53. The company has a 50-day simple moving average of $9.04 and a 200-day simple moving average of $7.75. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The business had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. As a group, research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Insiders Place Their Bets

In other Xeris Biopharma news, insider Beth Hecht sold 16,666 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.41, for a total transaction of $156,827.06. Following the sale, the insider directly owned 1,111,130 shares in the company, valued at approximately $10,455,733.30. The trade was a 1.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.41, for a total transaction of $47,050.00. Following the sale, the insider owned 1,351,053 shares in the company, valued at $12,713,408.73. The trade was a 0.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 134,998 shares of company stock worth $1,202,666. 4.35% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xeris Biopharma

Large investors have recently made changes to their positions in the stock. Allworth Financial LP lifted its stake in shares of Xeris Biopharma by 86.4% in the second quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock valued at $34,000 after purchasing an additional 2,000 shares during the period. AlphaCentric Advisors LLC boosted its holdings in Xeris Biopharma by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock worth $266,000 after buying an additional 2,494 shares in the last quarter. GK Wealth Management LLC purchased a new stake in Xeris Biopharma during the third quarter worth about $32,000. KBC Group NV purchased a new stake in Xeris Biopharma during the first quarter worth about $27,000. Finally, Royal Bank of Canada boosted its holdings in Xeris Biopharma by 12.9% during the first quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock worth $253,000 after buying an additional 4,974 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.